Rapid Micro Q2 commercial revenue $5.7M (+135% YoY); full-year outlook at least $24M

RAPID MICRO BIOSYSTEMS, INC.

2021-Q2 EPS reported -$57.17 revenue$11,125,000

Q2 total revenue $6.1M vs $2.6M YoY; net loss ($11.8M) vs ($9.3M) YoY.
Placed 8 new systems (cumulative 103); validated 11 systems (cumulative 63).
Sold one-millionth consumable since Growth Direct commercial launch.
Completed IPO in July 2021: ~9M shares sold, $165.3M net proceeds; pro forma cash ~$260M.
Full-year 2021 commercial revenue guidance: at least $24.0M (≥70% YoY growth).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.